RxSight(RXST.US) Director Buys US$305.46K in Common Stock
$RxSight(RXST.US)$ Director Tammenoms Bakker Juliet purchased 5,000 shares of common stock on May 17, 2024 at an average price of $61.0913 for a total value of $305.46K.Source: Announcement What is st
Rxsight Insider Bought Shares Worth $305,457, According to a Recent SEC Filing
Juliet Tammenoms Bakker, Director, on May 17, 2024, executed a purchase for 5,000 shares in Rxsight (RXST) for $305,457. Following the Form 4 filing with the SEC, Bakker has control over a total of 36
RxSight Raises $115 Million From Public Offering of Shares
RxSight (RXST) said it raised $115 million in gross proceeds from an underwritten public offering of nearly 2.1 million shares at $56 apiece. The offering includes full exercise by the underwriters of
Press Release: RxSight, Inc. Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Rx
RxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$72.75
Why RxSight (RXST) Shares Are Falling
RxSight Inc (NASDAQ:RXST) shares are roughly flat following earlier weakness during Thursday's session after the company announced pricing of its $100 million proposed public offering of common stock.
RxSight Price Raises Equity at $56 per Share
Reported Earlier, RxSight Prices Public Offering Of 1,785,714 Common Stock At $56/Share
RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857
RxSight To Sell About 1.79 Mln Shares At $56.00/shr; Stock Down
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
RxSight Shares Are Trading Lower After the Company Announced a $100 Million Proposed Public Offering of Common Stock.
RxSight Shares Are Trading Lower After the Company Announced a $100 Million Proposed Public Offering of Common Stock.
RxSight Announces $100M Proposed Public Offering Of Common Stock
RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offe
RxSight Announces Proposed Offering of Common Stock
RxSight Files Automatic Mixed Shelf
RxSight, Inc. Announces Proposed Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
Press Release: RxSight, Inc. Announces Proposed Public Offering of Common Stock
RxSight, Inc. Announces Proposed Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to
RxSight's Strong Q1 Performance and Market Expansion Justify Buy Rating
RxSight Is Maintained at Overweight by Wells Fargo
RxSight Is Maintained at Overweight by Wells Fargo
Wells Fargo: Maintaining the RxSight (RXST.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $61.00 to $68.00.
Wells Fargo: Maintaining the RxSight (RXST.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $61.00 to $68.00.
Wells Fargo Maintains Overweight on RxSight, Raises Price Target to $68
Wells Fargo analyst Larry Biegelsen maintains RxSight with a Overweight and raises the price target from $61 to $68.